Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha

G. Barbaro, G. Di Lorenzo, M. Soldini, G. Gianeaspro, A. Pellicelli, B. Grisorio, G. Barbarini, F. De Rosa, F. Cadario, D. Capelli, G. Filice, A. Paiano, G. Belloni, L. Ferrari, G. Gualandi, I. Poltronieri, A. Barelli, P. Rocchetto, P. Del Poggio, G. BellomoG. Calleri, G. Cariti, L. Fruttaldo, F. Mongiò, G. Rizzo, M. Annese, G. Scotto, D. Bacca, R. Francavilla

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.

Original languageEnglish
Pages (from-to)928-933
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume34
Issue number9
DOIs
Publication statusPublished - 1999

Keywords

  • Chronic hepatitis C
  • Interferon-alpha
  • Interferon-beta
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha'. Together they form a unique fingerprint.

Cite this